| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.19 | 4e-09 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-06 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.18 | 6e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.21 | 5e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.19 | 6e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.2 | 6e-05 |